Protalix Biotherapeutics, Inc. (PLX) - Comprehensive Stock Analysis & Investment Research
Deep dive into Protalix Biotherapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.
Protalix Biotherapeutics, Inc. Investment Summary
When evaluating whether Protalix Biotherapeutics, Inc. (PLX) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.
Company Profile
Protalix Biotherapeutics, Inc. (PLX) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. The company employs approximately 266 people. With a market capitalization of $225 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.
Financial Performance Analysis
Our comprehensive financial analysis covers Protalix Biotherapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...
AI Price Predictions
Get AI-powered 7-day, 30-day and 90-day price forecasts for Protalix Biotherapeutics, Inc. along with confidence scores and detailed analysis...
Investment Considerations
Expert analysis of whether Protalix Biotherapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...
Corporate Identity
Protalix Biotherapeutics, Inc. (Stock Symbol: PLX) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the NYSE exchange.
Leadership & Workforce
Detailed information about Protalix Biotherapeutics, Inc.'s leadership team, workforce size, and organizational structure...
Market Classification
Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Protalix Biotherapeutics, Inc....
Sector & Industry Analysis
In-depth sector dynamics and industry context for Protalix Biotherapeutics, Inc....
Revenue & Growth Analysis
Protalix Biotherapeutics, Inc. generates annual revenues of $61 million , representing an emerging company in its growth phase.
Profitability Metrics
Net profit margin, gross margin, and operating margin analysis for Protalix Biotherapeutics, Inc....
Market Valuation
P/E ratio, price-to-book, and valuation multiples for Protalix Biotherapeutics, Inc....
Return Metrics
Return on equity (ROE), return on assets (ROA), and capital efficiency for Protalix Biotherapeutics, Inc....
Strategic Market Position
Protalix Biotherapeutics, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.
Industry Competitive Landscape
Protalix Biotherapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.
Operational Efficiency
The company currently shows negative free cash flow of $-8 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.
Margin & Pricing Power Analysis
The company maintains a 14.3% gross margin characteristic of commodity-like businesses or high-volume, low-margin operators. Thin gross margins require exceptional operational efficiency and volume to generate meaningful profits. Companies at this margin level are particularly sensitive to cost increases or pricing pressures.
Operating margin of -185.6% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.
Asset Utilization Efficiency
Asset turnover ratio of 0.50x indicates moderate asset turnover common in capital-intensive industries such as utilities, real estate, or heavy manufacturing. Lower turnover in these sectors is expected due to the significant infrastructure required for operations.
Financial Strength & Leverage
Current ratio of 1.60 indicates adequate liquidity to meet short-term obligations with reasonable cushion. This level balances working capital efficiency with financial safety.